Abstract:Osteogenesis imperfecta (OI), an inherited connective tissue disorder of remarkable clinical variability, is caused by a quantitative or qualitative defect in collagen synthesis and is characterised by bone fragility. The number of fractures and deformities, and the age at which they begin greatly influence the prognosis and the achievement of walking and autonomy. A multidisciplinary team approach is essential for diagnosis, for communication with patient and parents, and to tailor treatment needs to the severity of the disease and the age of the patient. Three types of treatment are available: nonsurgical management (physical therapy, rehabilitation, bracing and splinting), surgery (intramedullary rod positioning, spinal and basilar impression surgery), and drugs to increase the strength of bone and decrease the number of fractures. An aggressive rehabilitative approach is indicated to optimise functional ability and walking capacity; appropriately timed surgery to insert intramedullary rods provides improved function of extremities. Despite a high rate of complications, intramedullary telescopic roding has proven to be the most successful method for preventing and correcting fractures and deformities of long bones, improving walking capability and leading to successful rehabilitation of even severely affected patients. Surgery may be required in patients with progressive spinal deformity and in those with symptomatic basilar impression. Hearing function, dentinogenesis imperfecta, cardiac and respiratory function, and neurological changes must be monitored. The causal defect of the disease cannot be corrected with medical treatment and, currently, only symptomatic therapy is available. In recent years growth hormone (GH) and bisphosphonate agents have been used in OI therapy. GH is beneficial in patients with moderate forms of OI, showing a positive effect on bone turnover, bone mineral density and height velocity rate. Bisphosphonates have proved beneficial in children with severe OI, increasing bone mineral density and reducing the fracture rate and pain with no adverse effects reported. These data require confirmation in double-blind controlled studies; however, bisphosphonates have markedly improved morbidity in patients with OI. Future developments in genetic therapy may be directed towards either replacing cells carrying the mutant gene with normal cells or silencing the mutant allele using antisense suppression therapy, thus transforming a biochemically severe form of OI into a mild form.

Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta

Genotype-Phenotype Relationship and Follow-up Analysis of a Chinese Cohort with Osteogenesis Imperfecta

Genotypic And Phenotypic Characteristics Of 29 Patients With Rare Types Of Osteogenesis Imperfecta: Average 5 Years Of Follow-Up

Genotype and Phenotype Analysis of Taiwanese Patients with Osteogenesis Imperfecta

Genotype-phenotype correlations in 294 pediatric patients with osteogenesis imperfecta

Genotype and Phenotype Correlation of Patients with Osteogenesis Imperfecta

Genotype-Phenotype Association Analysis Reveals New Pathogenic Factors for Osteogenesis Imperfecta Disease.

Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.

Pleiotropic effects of a recessive C mutation occurring in a mouse model of severe osteogenesis imperfecta

High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1

Current concepts in osteogenesis imperfecta: Bone structure, biomechanics and medical management

Clinical spectrum of rare bone fragility disorders and response to bisphosphonate treatment: a retrospective study

Management of Osteogenesis Imperfecta

Genotype–phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta

Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta

Association of trabecular bone score and bone mineral apparent density with the severity of bone fragility in children and adolescents with osteogenesis imperfecta: A cross-sectional study

NOVEL MUTATIONS IN THE WNT1, TMEM38B, P4HB, AND PLS3 GENES IN FOUR UNRELATED CHINESE FAMILIES WITH OSTEOGENESIS IMPERFECTA.

Osteogenesis imperfecta: practical treatment guidelines

Clinical and genetic analysis in 185 Chinese probands of osteogenesis imperfecta

Novel mutations in BMP1 result in a patient with autosomal recessive osteogenesis imperfecta

Effectiveness of whole exome sequencing analyses in the molecular diagnosis of osteogenesis imperfecta